<DOC>
	<DOCNO>NCT02005315</DOCNO>
	<brief_summary>This open-label Phase 1b dose-escalation study ass safety , tolerability , PK vantictumab combine nab-paclitaxel gemcitabine .</brief_summary>
	<brief_title>A Study Vantictumab ( OMP-18R5 ) Combination With Nab-Paclitaxel Gemcitabine Previously Untreated Stage IV Pancreatic Cancer</brief_title>
	<detailed_description>Once maximum tolerate dose ( MTD ) maximum administer dose ( MAD ) determine , 10 patient may enrol cohort-expansion phase well characterize safety , tolerability PK vantictumab combine nab-paclitaxel gemcitabine . Up approximately 34 patient may enrol study .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Signed Informed Consent Form Age â‰¥18 year Histologically document Stage IV ductal adenocarcinoma pancreas Availability tumor tissue , either archival FFPE obtain study entry fresh biopsy ECOG performance status 0 1 Adequate hematologic endorgan function Evaluable measurable disease per RECIST v1.1 For woman childbearing potential men partner childbearing potential , agreement use two effective form contraception Prior therapy Day 1 Cycle 1 treatment Stage IV pancreatic cancer Prior adjuvant therapy treatment ductal adenocarcinoma pancreas Known hypersensitivity component study treatment Known brain metastasis , uncontrolled seizure disorder , active neurologic disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Pancreatic Cancer</keyword>
	<keyword>Stage IV Pancreatic Cancer</keyword>
</DOC>